Project Grant R21AI186566
Award Date
11/15/24
Completion Date
10/31/26
Dollars Obligated
$186K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72205, USA
Similar Awards
This Project Grant award of $877,104 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the interactions between Kaposi's sarcoma-associated herpesvirus (KSHV), mononuclear phagocytes, and B cells, and how KSHV establishes long-term latency in B cells. The research, conducted by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will use computational...
This $420,335 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on understanding the role of lytic viral gene expression in the development and maintenance of oncogenic gammaherpesvirus-associated cancers. The University of Arkansas for Medical Sciences (UAMS) is leading this 2-year research project to test the hypothesis that lytic gene expression is...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), provides $583,289 to the University of Arkansas for Medical Sciences to conduct research on the epigenetic regulation of Kaposi's sarcoma-associated herpesvirus (KSHV) latency. The research aims to advance understanding of how KSHV, which causes several AIDS-defining malignancies including Kaposi's sarcoma, can...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $430,285.00 to Towson University to investigate RTA-induced ubiquitination in Kaposi's Sarcoma Herpesvirus (KSHV) and identify potential cellular targets and small molecule inhibitors for intervention. The 3-year project aims to evaluate the impact of RTA target modification/degradation on KSHV latency...
This $306,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to determine the role of Macrophage Migration Inhibitory Factor (MIF) signaling in Kaposi's Sarcoma-associated Herpesvirus (KSHV) pathogenesis and oncogenesis. The research aims to: 1) Determine the mechanisms of MIF signaling activation in KSHV-positive tumor cells, and 2) Develop MIF-targeted...
The University of Florida was awarded a $402,150 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The award, effective July 23, 2025 through June 30, 2027, supports research into the viral mechanisms by which Kaposi's sarcoma-associated herpesvirus (KSHV) engages host transcription factors to promote its lytic replication cycle. The project aims to uncover the protein...
This federal Project Grant award, with ID R01CA290700, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $564,698 award to the University of California, Davis (UC Davis) will fund a 5-year research project to investigate the role of the terminal repeat sequence in regulating the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic gene promoters. The research aims to better understand the KSHV gene regulation mechanisms, with the...
This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $411,400 to Northwestern University to develop and characterize a cell culture model of Kaposi's sarcoma (KS). The primary objective is to identify KSHV-induced cellular genes that promote the loss of contact inhibition of proliferation (CIP) in KSHV-infected lymphatic endothelial cells (KLECs), which are believed to be the cell of origin for KS tumors. The...
This Project Grant award of $188,169.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The key objectives are to complete proof-of-concept studies evaluating the biological activity and efficacy of the AAV vector in killing cancer cells through in vitro assays and xenograft mouse models. The...